In the SURMOUNT-1 clinical trial, patients without diabetes lost an average of 15-21% of baseline body weight over 72 weeks, depending on dosage, with somewhat lower averages observed in patients with type 2 diabetes in SURMOUNT-2
Notably, ablation of vagal inputs, whether by surgical or chemical methods, has been shown to block the appetite-suppressing effects of peripheral GLP-1 in rodent models (Abbott et al., 2005
Immunoblot images are cropped from the chemiluminescence signal files
Damage those cells and you may lose hearing, develop tinnitus, or feel unsteady
There is no strong evidence showing higher depression risk compared to other weight loss drugs
For related materials, see Bacteriostatic Water 10 ml and the individual product pages: BPC-157, TB-500, GHK-Cu, and KPV